CERAB Technique for Aortoiliac Occlusive Disease
Primary Purpose
Aortoiliac Occlusive Disease
Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Covered Endovacular Reconstruction of Aortic Bifurcation
Sponsored by
About this trial
This is an interventional treatment trial for Aortoiliac Occlusive Disease
Eligibility Criteria
Inclusion Criteria:
- Age: 18 years and older patients.
- Patient presented with disabling claudication pain.
- Patient presented with rest pain.
- Patient presented with gangrene or atrophic changes.
- Provided written informed consent.
- Eligible anatomy for CERAB technique.
- TASC- (II) classification as assigned in the study protocol (specified type B, C and D lesions).
Exclusion Criteria:
- Age less than 18 years old.
- Patients with acute limb ischemia.
- Patients treated with open surgery and other endovascular techniques such as kissing stenting.
- CERAB configuration extending into aneurysmatic infrarenal aorta.
- Patient's life expectancy <2 years as judged by the investigator.
- Patient has a psychiatric or other condition that may interfere with the study.
- Patient has a known allergy to any device component.
- Patients with a systemic infection who may be at increased risk of endovascular graft infection.
- Patient has a coagulopathy or uncontrolled bleeding disorder.
- Patient had a recent cerebrovascular accident (CVA) or a myocardial infarction (MI) within the prior three months.
- Patient is pregnant (Female patients of childbearing potential only).
Sites / Locations
Arms of the Study
Arm 1
Arm Type
Other
Arm Label
Aortoiliac occlusive disease
Arm Description
This study will be carried out on patients with extensive Aortoiliac occlusive disease using the CERAB technique.
Outcomes
Primary Outcome Measures
Primary patency
uninterrupted patency in the absence of re-stenosis or occlusion, without any procedures performed on the vessel or stent.
Technical success
successful implantation of the CERAB device restoring blood flow with <30% residual stenosis without conversion to open repair during the 30-days after implantation
Secondary Outcome Measures
Secondary patency
patency achieved by all procedures aimed at recanalizing an occluded CBES, thereby preserving the endograft.
Freedom from target lesion revascularization (TLR)
an open endograft without procedures performed for re-stenosis or occlusion leading to symptoms requiring an intervention.
Clinical improvement
hemodynamic improvement with an increase of at least 0.10 in ABI, combined with a symptomatic improvement of at least one Rutherford category.
Re-stenosis
a lesion with a peak systolic value (PSV) ratio >2.5 as measured in the endograft and proximal or distal to the endograft or an angiographic diameter reduction of >50%.
Limb salvage rate
all patients without above ankle amputations
Minor complications
those that were only temporary leading to impairment, whereas major complications were defined by permanent damage or death.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT04148456
Brief Title
CERAB Technique for Aortoiliac Occlusive Disease
Official Title
Covered Endovascular Reconstruction of Aortic Bifurcation (CERAB) Technique for Extensive Aortoiliac Occlusive Disease
Study Type
Interventional
2. Study Status
Record Verification Date
July 2020
Overall Recruitment Status
Not yet recruiting
Study Start Date
January 1, 2021 (Anticipated)
Primary Completion Date
December 1, 2023 (Anticipated)
Study Completion Date
January 1, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Assiut University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
To evaluate the safety and efficacy of the CERAB technique as an alternative to surgical reconstruction for treatment of aorto-iliac occlusive disease.
Detailed Description
According to the Trans-Atlantic Inter-society Consensus (TASC-II), bypass grafting is the treatment of choice for extensive aortoiliac occlusive disease (AIOD) due to the good long-term patency rates. However, surgical reconstruction is associated with peri-operative morbidity and mortality.
Kissing stent technique was introduced as an endovascular treatment alternative for bilateral aortoiliac occlusive disease in 1991. Reported technical success rates varied with the use of bare metal stents in extensive AOID.
The COBEST trial showed that covered balloon expandable stents (CBES) have a superior primary patency rate and clinical improvement outcome at 24 months when compared with bare metal stents. CBES may immediately reduce the risk of procedural complications such as dissection, perforation, in-stent stenosis, and embolization.
In 2013, CERAB technique was introduced to improve endovascular treatment results by a more anatomical and physiological reconstruction, with a subsequent better clinical outcome.
The CERAB technique was developed to overcome the anatomical and physiological disadvantages of kissing stents such as flow disturbances leading to turbulence and stasis of blood, which may cause thrombus formation and intimal neohyperplasia.
The early results of the CERAB configuration are promising at 1-year follow up in a group of 130 patients with AOID and the 30-day major complication rate was 7.7%.
CERAB and Chimney CERAB (C-CERAB) techniques may change the treatment algorithm of AIOD and juxta-renal occlusive disease. It appears to be a safe and feasible alternative with promising results, being a valid alternative for surgery and/or kissing stents.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Aortoiliac Occlusive Disease
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
53 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Aortoiliac occlusive disease
Arm Type
Other
Arm Description
This study will be carried out on patients with extensive Aortoiliac occlusive disease using the CERAB technique.
Intervention Type
Procedure
Intervention Name(s)
Covered Endovacular Reconstruction of Aortic Bifurcation
Intervention Description
The occlusive lesion is then passed, either subintimal or endoluminal, using crossing wires and catheters.
After gaining re-entry into the lumen of the aorta, angiography will be confirmed proper positioning for those with a subintimal passage.
A 10-12 mm V12 LD balloon expandable ePTFE covered stent (Atrium Medical, Maquet Getinge Group, Hudson, NH) will be expanded in the distal aorta approximately 20 mm above the bifurcation through the 9 Fr sheath.
The proximal 2/3 part of the aortic stent will be flared with a larger balloon, usually 16 mm, thereby creating a funnel shaped covered stent. Subsequently, two 8 mm V12 balloon expandable ePTFE covered stents (Atrium Medical, Maquet Getinge Group, Hudson, NH) will be placed proximally in the distal 1/3 of the aortic stent, and then simultaneously deployed distally into the common iliac arteries creating a tight connection with the first aortic stent, thereby creating the new aortic bifurcation.
Primary Outcome Measure Information:
Title
Primary patency
Description
uninterrupted patency in the absence of re-stenosis or occlusion, without any procedures performed on the vessel or stent.
Time Frame
12 months
Title
Technical success
Description
successful implantation of the CERAB device restoring blood flow with <30% residual stenosis without conversion to open repair during the 30-days after implantation
Time Frame
1 month
Secondary Outcome Measure Information:
Title
Secondary patency
Description
patency achieved by all procedures aimed at recanalizing an occluded CBES, thereby preserving the endograft.
Time Frame
12 months
Title
Freedom from target lesion revascularization (TLR)
Description
an open endograft without procedures performed for re-stenosis or occlusion leading to symptoms requiring an intervention.
Time Frame
12 months
Title
Clinical improvement
Description
hemodynamic improvement with an increase of at least 0.10 in ABI, combined with a symptomatic improvement of at least one Rutherford category.
Time Frame
12 months
Title
Re-stenosis
Description
a lesion with a peak systolic value (PSV) ratio >2.5 as measured in the endograft and proximal or distal to the endograft or an angiographic diameter reduction of >50%.
Time Frame
12 months
Title
Limb salvage rate
Description
all patients without above ankle amputations
Time Frame
12 months
Title
Minor complications
Description
those that were only temporary leading to impairment, whereas major complications were defined by permanent damage or death.
Time Frame
12 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age: 18 years and older patients.
Patient presented with disabling claudication pain.
Patient presented with rest pain.
Patient presented with gangrene or atrophic changes.
Provided written informed consent.
Eligible anatomy for CERAB technique.
TASC- (II) classification as assigned in the study protocol (specified type B, C and D lesions).
Exclusion Criteria:
Age less than 18 years old.
Patients with acute limb ischemia.
Patients treated with open surgery and other endovascular techniques such as kissing stenting.
CERAB configuration extending into aneurysmatic infrarenal aorta.
Patient's life expectancy <2 years as judged by the investigator.
Patient has a psychiatric or other condition that may interfere with the study.
Patient has a known allergy to any device component.
Patients with a systemic infection who may be at increased risk of endovascular graft infection.
Patient has a coagulopathy or uncontrolled bleeding disorder.
Patient had a recent cerebrovascular accident (CVA) or a myocardial infarction (MI) within the prior three months.
Patient is pregnant (Female patients of childbearing potential only).
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
omar M Abd Elhakam, Doctor
Phone
01064991946
Email
omarhejazy@ymail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
omar M Abd Elhakam, Doctor
Organizational Affiliation
Assiut University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Ayman E Hassaballah, Professor
Organizational Affiliation
Assiut University
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Haitham A Hassan, Doctor
Organizational Affiliation
Assiut University
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Ahmed K Sayed, Doctor
Organizational Affiliation
Assiut University
Official's Role
Study Chair
12. IPD Sharing Statement
Citations:
PubMed Identifier
17223489
Citation
Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG; TASC II Working Group. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg. 2007 Jan;45 Suppl S:S5-67. doi: 10.1016/j.jvs.2006.12.037. No abstract available.
Results Reference
background
PubMed Identifier
1878908
Citation
Kuffer G, Spengel F, Steckmeier B. Percutaneous reconstruction of the aortic bifurcation with Palmaz stents: case report. Cardiovasc Intervent Radiol. 1991 May-Jun;14(3):170-2. doi: 10.1007/BF02577722. No abstract available.
Results Reference
background
PubMed Identifier
22695260
Citation
Grimme FA, Goverde PA, Van Oostayen JA, Zeebregts CJ, Reijnen MM. Covered stents for aortoiliac reconstruction of chronic occlusive lesions. J Cardiovasc Surg (Torino). 2012 Jun;53(3):279-89.
Results Reference
background
PubMed Identifier
17308516
Citation
Bosiers M, Iyer V, Deloose K, Verbist J, Peeters P. Flemish experience using the Advanta V12 stent-graft for the treatment of iliac artery occlusive disease. J Cardiovasc Surg (Torino). 2007 Feb;48(1):7-12.
Results Reference
background
PubMed Identifier
23210879
Citation
Grimme FA, Spithoven JH, Zeebregts CJ, Scharn DM, Reijnen MM. Midterm outcome of balloon-expandable polytetrafluoroethylene-covered stents in the treatment of iliac artery chronic occlusive disease. J Endovasc Ther. 2012 Dec;19(6):797-804. doi: 10.1583/JEVT-12-3941MR.1.
Results Reference
background
PubMed Identifier
25218651
Citation
Grimme FA, Reijnen MM, Pfister K, Martens JM, Kasprzak P. Polytetrafluoroethylene covered stent placement for focal occlusive disease of the infrarenal aorta. Eur J Vasc Endovasc Surg. 2014 Nov;48(5):545-50. doi: 10.1016/j.ejvs.2014.08.009. Epub 2014 Sep 11.
Results Reference
background
PubMed Identifier
20538478
Citation
Sabri SS, Choudhri A, Orgera G, Arslan B, Turba UC, Harthun NL, Hagspiel KD, Matsumoto AH, Angle JF. Outcomes of covered kissing stent placement compared with bare metal stent placement in the treatment of atherosclerotic occlusive disease at the aortic bifurcation. J Vasc Interv Radiol. 2010 Jul;21(7):995-1003. doi: 10.1016/j.jvir.2010.02.032. Epub 2010 Jun 11.
Results Reference
background
PubMed Identifier
1839237
Citation
Palmaz JC, Encarnacion CE, Garcia OJ, Schatz RA, Rivera FJ, Laborde JC, Dougherty SP. Aortic bifurcation stenosis: treatment with intravascular stents. J Vasc Interv Radiol. 1991 Aug;2(3):319-23. doi: 10.1016/s1051-0443(91)72250-1.
Results Reference
background
PubMed Identifier
21906903
Citation
Mwipatayi BP, Thomas S, Wong J, Temple SE, Vijayan V, Jackson M, Burrows SA; Covered Versus Balloon Expandable Stent Trial (COBEST) Co-investigators. A comparison of covered vs bare expandable stents for the treatment of aortoiliac occlusive disease. J Vasc Surg. 2011 Dec;54(6):1561-70. doi: 10.1016/j.jvs.2011.06.097. Epub 2011 Sep 9.
Results Reference
background
PubMed Identifier
23640357
Citation
Goverde PC, Grimme FA, Verbruggen PJ, Reijnen MM. Covered endovascular reconstruction of aortic bifurcation (CERAB) technique: a new approach in treating extensive aortoiliac occlusive disease. J Cardiovasc Surg (Torino). 2013 Jun;54(3):383-7.
Results Reference
background
PubMed Identifier
10735428
Citation
Saker MB, Oppat WF, Kent SA, Ryu RK, Chrisman HB, Nemcek AA, Pearce W, Pearce W, Vogelzang R. Early failure of aortoiliac kissing stents: histopathologic correlation. J Vasc Interv Radiol. 2000 Mar;11(3):333-6. doi: 10.1016/s1051-0443(07)61426-2. No abstract available.
Results Reference
background
PubMed Identifier
27012930
Citation
Taeymans K, Goverde P, Lauwers K, Verbruggen P. The CERAB technique: tips, tricks and results. J Cardiovasc Surg (Torino). 2016 Jun;57(3):343-9. Epub 2016 Mar 24.
Results Reference
background
PubMed Identifier
24486037
Citation
Groot Jebbink E, Grimme FA, Goverde PC, van Oostayen JA, Slump CH, Reijnen MM. Geometrical consequences of kissing stents and the Covered Endovascular Reconstruction of the Aortic Bifurcation configuration in an in vitro model for endovascular reconstruction of aortic bifurcation. J Vasc Surg. 2015 May;61(5):1306-11. doi: 10.1016/j.jvs.2013.12.026. Epub 2014 Jan 29.
Results Reference
background
PubMed Identifier
26343310
Citation
Grimme FA, Goverde PC, Verbruggen PJ, Zeebregts CJ, Reijnen MM. Editor's Choice--First Results of the Covered Endovascular Reconstruction of the Aortic Bifurcation (CERAB) Technique for Aortoiliac Occlusive Disease. Eur J Vasc Endovasc Surg. 2015 Nov;50(5):638-47. doi: 10.1016/j.ejvs.2015.06.112. Epub 2015 Sep 3.
Results Reference
background
PubMed Identifier
9308598
Citation
Rutherford RB, Baker JD, Ernst C, Johnston KW, Porter JM, Ahn S, Jones DN. Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg. 1997 Sep;26(3):517-38. doi: 10.1016/s0741-5214(97)70045-4. Erratum In: J Vasc Surg 2001 Apr;33(4):805.
Results Reference
background
Learn more about this trial
CERAB Technique for Aortoiliac Occlusive Disease
We'll reach out to this number within 24 hrs